Forian Inc.

03/27/2026 | Press release | Distributed by Public on 03/27/2026 14:16

Forian Inc. Announces Fourth Quarter and Full Year 2025 Financial Results (Form 8-K)

Forian Inc.
Announces Fourth Quarter and Full Year 2025 Financial Results

Newtown, PA, March 27, 2026 (GLOBE NEWSWIRE) - Forian Inc. (Nasdaq: FORA), a leading provider of data science driven information and analytics solutions to the life science, healthcare and financial services industries, today announced results for the quarter and year ended December 31, 2025.

"In 2025, we demonstrated that disciplined cost management and strategic investment can go hand in hand," said Chief Executive Officer Max Wygod. "We grew our business, expanded into new markets, and made targeted investments in our data platform and product development while maintaining a cost-conscious approach that preserved the strength of our balance sheet."

Fourth Quarter 2025 Financial Results

Forian delivered the following results for the fourth quarter of 2025:

Three Months Ended
December 31,

2025
Unaudited
2024
Unaudited
Period-over-
Period %
Change
Revenue
$
7,962,480
$
5,812,472
37
%
Net income (loss)
$
(1,821,752
)
$
199,711
-1012
%
Net loss per share - diluted
$
(0.06
)
$
0.01
-700
%
Adjusted EBITDA (a non-GAAP financial measure defined below below)
$
(170,531
)
$
120,599
-241
%


●
Revenue for the quarter was $8.0 million, a $2.2 million increase from $5.8 million in the prior year

●
Net loss for the quarter was $(1.8) million, or $(0.06) per share, compared to a net income of $0.2 million, or $0.01 per share, in the prior year

●
Adjusted EBITDA for the quarter was $(0.2) million, compared to $0.1 million in the prior year

●
Cash, cash equivalents and marketable securities at December 31, 2025 totaled $31.6 million

Full Year 2025 Financial Results

Forian delivered the following results for the full year 2025:


Twelve Months Ended
December 31,

2025
Unaudited
2024
Unaudited
Period-over-
Period %
Change
Revenue
$
30,256,919
$
20,153,263
50
%
Net loss
$
(2,874,042
)
$
(3,771,070
)
24
%
Net loss per share - diluted
$
(0.09
)
$
(0.12
)
25
%
Adjusted EBITDA (a non-GAAP financial measure defined below below)
$
840,408
$
489,134
72
%


●
Revenue for the full year was $30.3 million, a $10.1 million increase from $20.2 million in the prior year

●
Net loss for the full year was $(2.9) million, or $(0.09) per share, compared to a net loss of $(3.8) million, or $(0.12) per share, in the prior year

●
Adjusted EBITDA for the full year was $0.8 million, compared to $0.5 million in the prior year

Full Year 2025 Highlights


●
Achieved Revenue Guidance Target: Delivered Forian's strong quarterly revenue performance to close the year, driven by key contract renewals that offset churn and data supply headwinds

●
Delivered on Adj. EBITDA Guidance: Achieved the targeted margin profile for the year while continuing to make meaningful investments across the business

●
Strengthened Data Platform and Partnerships: Expanded contracting activity and onboarded new clinical data feeds, addressing upstream data supply challenges and broadening the Company's data foundation

●
Growing Pharmaceutical and Biotech Footprint: Extended market penetration with life sciences customers, as pharmaceutical and biotech companies increasingly adopted Forian's data and analytics offerings

Corporate Development Update


●
On August 25, 2025, a consortium, led by Forian's Chief Executive Officer and Executive Chair (the "Consortium"), submitted a non-binding proposal to Forian's Board of Directors to acquire all of the outstanding shares of Common Stock not currently owned by the Consortium. A Special Committee that was formed to evaluate this proposal remains in place and is in discussions with the Consortium regarding the proposal. There can be no assurance that any transaction will result from these discussions, that the terms of any potential transaction will be acceptable to the Special Committee or Forian's Board of Directors, or as to the timing of any transaction. Forian does not intend to comment further on the status of these discussions unless and until a definitive agreement is reached or its Board otherwise determines that disclosure is appropriate or required.

Non-GAAP Financial Measures

This release uses non-GAAP financial measures that are adjusted for the impact of various U.S. GAAP items. See the section titled "Non-GAAP Financial Measures" and the table entitled "Reconciliation of U.S. GAAP to Non-GAAP Financial Measures" below for details.

About Forian

Forian provides a unique suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences and healthcare payer and provider segments and, with its recent acquisition of Kyber Data Science, the financial services industry. Forian has industry leading expertise in acquiring, integrating, normalizing and commercializing large scale healthcare data assets. Forian's information products overlay sophisticated data management and data science capabilities on top of a comprehensive clinical data lake to identify unique relationships, create distinctive information assets and generate proprietary insights. For more information, please visit the Company's website at www.forian.com.

Forian Inc. published this content on March 27, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 27, 2026 at 20:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]